First Week of CTIC February 2015 Options Trading
StockOptionsChannel.com - Wed Dec 24, 11:46AM CST
Investors in CTI BioPharma Corp saw new options become available this week, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new February 2015 contracts and...
CTIC: 2.36 (+0.05)
Insider Trading Alert - CTIC, FXCM And CRM Traded By Insiders
at The Street - Mon Dec 22, 9:45AM CST
Stocks with insider trader activity include CTIC, FXCM and CRM
FXCM: 16.88 (-0.12), CTIC: 2.36 (+0.05), CRM: 60.33 (-0.17)
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), NBIX: 21.33 (+0.09), GILD: 91.29 (+1.84), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), CTIC: 2.36 (+0.05), CEMP: 20.66 (+0.78), BMY: 59.15 (-0.01)
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 115.15 (+1.40), MYGN: 36.50 (+0.28), DNDN: 0.13 (-0.02), CTIC: 2.36 (+0.05), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Bone Degeneration - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/mtq3mr/bone_degeneration) has announced the addition of the "Bone Degeneration - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Degeneration and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alethia Biotherapeutics Inc. - Calzada Limited - CTI BioPharma Corp. - GliaMed, Inc. - Histocell S.L. - TechnoPhage SA - TissueGene, Inc. For more information visit http://www.researchandmarkets.com/research/mt...generation
CTIC: 2.36 (+0.05)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.63 (-0.04), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), ONTX: 3.82 (+0.06), CTIC: 2.36 (+0.05), BMY: 59.15 (-0.01), STML: 15.53 (+0.23), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)
CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells
PR Newswire - Tue Dec 09, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays. The findings from this study were presented by Dr. Ceri Marrin, Consultant Haematologist, University Hospital of Wales at Cardiff University, during an oral presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9 in San Francisco, CA.
CTIC: 2.36 (+0.05)
Insider Trading Alert - CSU, IRBT And CTIC Traded By Insiders
at The Street - Mon Dec 08, 9:45AM CST
Stocks with insider trader activity include CSU, IRBT and CTIC
CSU: 25.08 (+0.10), CTIC: 2.36 (+0.05), IRBT: 34.94 (-0.11)
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/jtddt5/postpolycythemia) has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - Gilead Sciences - Novartis - Nippon Shinyaku - CTI BioPharma - Incyte - Italfarmaco - Promedior - Pharma Mar For more information visit http://www.researchandmarkets.com/research/jt...lycythemia
GILD: 91.29 (+1.84), CTIC: 2.36 (+0.05), NVS: 93.91 (+0.66)
CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers
PR Newswire - Sat Dec 06, 11:00AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. Researchers presented the findings from this analysis at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9 in San Francisco, CA.
CTIC: 2.36 (+0.05)
CTI BioPharma earns $15M milestone
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:46AM CST
TEVA: 57.09 (+0.33), CTIC: 2.36 (+0.05)
CTI BioPharma awarded USD15m milestone payment for TRISENOX
M2 - Thu Dec 04, 6:25AM CST
Biopharmaceutical company CTI BioPharma (NASDAQ:CTIC)(MTA:CTIC) reported on Thursday the receipt of USD15m milestone payment from Teva Pharmaceutical Industries related to the achievement of sales milestones for TRISENOX (arsenic trioxide).
TEVA: 57.09 (+0.33), CTIC: 2.36 (+0.05)
CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX®
PR Newswire - Thu Dec 04, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $15 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI is eligible to receive up to an additional $80 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.
TEVA: 57.09 (+0.33), CTIC: 2.36 (+0.05)
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
at The Street - Tue Dec 02, 10:00AM CST
Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
AGEN: 3.85 (unch), BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CYTR: 2.58 (+0.03), SNSS: 2.48 (-0.03), CTIC: 2.36 (+0.05), NVS: 93.91 (+0.66)
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics
PR Newswire - Tue Dec 02, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corporation (NASDAQ: CTIC), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), iBio Inc. (NYSE MKT: IBIO), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 01, 2014, the NASDAQ Composite ended at 4,727.35, down 1.34%, the Dow Jones Industrial Average edged 0.29% lower, to finish the day at 17,776.80, and the S&P 500 closed at 2,053.44, down 0.68%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 802.07, down 0.20%, while the index has advanced 8.74% in the previous three months. Register for your complimentary reports on these five stocks at:
PGNX: 6.99 (-0.03), VRTX: 115.15 (+1.40), NLNK: 39.08 (+1.36), IBIO: 0.68 (-0.04), CTIC: 2.36 (+0.05)
Why CTI BioPharma Corp. Stock Tumbled 10% in November
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 02, 7:41AM CST
CTIC data by YCharts What: Shares of CTI BioPharma , a biopharmaceutical company focused on developing therapies to treat cancer, tumbled 10% in November, based on data from S&P Capital IQ , following its issuance of convertible...
CTIC: 2.36 (+0.05)
Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dnbkc/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh - JW Pharmaceutical - Karyopharm - Kyowa Hakko Kirin - Les Laboratoires Servier - MacroGenics - Merck & Co - Millennium - Novartis - Piramal - Plexxikon - Polaris - Seattle Genetics - SpectraMab - Sunesis - Synta - Targa - Tolero - Verastem, For more information visit http://www.researchandmarkets.com/research/7d...tory_acute
MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), AMBI: 15.60 (+0.26), GSK: 42.85 (+0.11), CTIC: 2.36 (+0.05), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)
Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/cbhmvq/relapsed_acute) has announced the addition of the "Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie - Actinium - Agios - Altor BioScience - Ambit Biosciences - Amgen - Astellas Pharma - Astex - AstraZeneca - AVEO - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Conkwest - Cornerstone - CTI BioPharma - Eisai - EpiZyme - Exelixis - F. Hoffmann-La Roche - Fujifilm Corporation - Genoscience Pharma - GlaxoSmithKline - Igenica Biotherapeutics - Incyte - Jiangsu Hansoh Pharmaceutical - JW Pharmaceutical - Karyopharm Therapeutics - Kyowa Hakko Kirin Co., Ltd. - Les Laboratoires Servier SAS - MacroGenics, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Piramal Enterprises Limited - Plexxikon Inc. - Polaris Group - Seattle Genetics, Inc. - Sunesis Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targa Therapeutics Corp. - Tolero Pharmaceuticals, Inc. - Verastem, Inc. For more information visit http://www.researchandmarkets.com/research/cb...psed_acute
MGNX: 33.00 (+0.34), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01), CTIC: 2.36 (+0.05), GSK: 42.85 (+0.11), VSTM: 8.30 (+0.19), SNTA: 2.63 (+0.02), SGEN: 31.10 (-0.14), MRK: 57.46 (+0.25), AMBI: 15.60 (+0.26), CELGZ: 3.34 (-0.01), KPTI: 37.78 (+1.28), NVS: 93.91 (+0.66)
CTI BioPharma Announces Data Presentations at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Dec 01, 12:30AM CST
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.
CTIC: 2.36 (+0.05)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), BMY: 59.15 (-0.01), CTIC: 2.36 (+0.05), NVS: 93.91 (+0.66)